XORTX Therapeutics Inc.
XRTX · XNASCIK 1729214fmd_00QXGZWE2CBGGE0TE3GGS36GXSManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2021, 3 periods
Latest annual · FY2021
Millions- Net income
- (2)
XORTX Therapeutics Inc. (XRTX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Net income | -CA$1.7 million | -CA$1.3 million | 20-F 2022-05-03 · proof | |
| Cash from operating activities | -CA$6.1 million | -CA$728,401 | 20-F 2022-05-03 · proof | |
| Total assets | CA$22 million | CA$2.3 million | +862.1% | 20-F 2022-05-03 · proof |
| Total liabilities | CA$5.3 million | CA$1 million | +412.3% | 20-F 2022-05-03 · proof |
| Cash and cash equivalents | CA$18.9 million | CA$171,271 | +10,906.7% | 20-F 2022-05-03 · proof |
- What was XORTX Therapeutics Inc. (XRTX)'s net income in fiscal 2021?
- XORTX Therapeutics Inc. (XRTX) reported net income of -CA$1.7 million for fiscal 2021 (the year ended Dec 31, 2021), against -CA$1.3 million the year before. Source: the 20-F filed with the SEC on May 3, 2022. SEC
- What was XORTX Therapeutics Inc. (XRTX)'s cash from operating activities in fiscal 2021?
- XORTX Therapeutics Inc. (XRTX) reported cash from operating activities of -CA$6.1 million for fiscal 2021 (the year ended Dec 31, 2021), against -CA$728,401 the year before. Source: the 20-F filed with the SEC on May 3, 2022. SEC
- What are XORTX Therapeutics Inc. (XRTX)'s total assets?
- As of Dec 31, 2021, XORTX Therapeutics Inc. (XRTX) reported total assets of CA$22 million, against CA$2.3 million a year earlier (+862.1%). Source: the 20-F filed with the SEC on May 3, 2022. SEC
- What are XORTX Therapeutics Inc. (XRTX)'s total liabilities?
- As of Dec 31, 2021, XORTX Therapeutics Inc. (XRTX) reported total liabilities of CA$5.3 million, against CA$1 million a year earlier (+412.3%). Source: the 20-F filed with the SEC on May 3, 2022. SEC
- What are XORTX Therapeutics Inc. (XRTX)'s cash and cash equivalents?
- As of Dec 31, 2021, XORTX Therapeutics Inc. (XRTX) reported cash and cash equivalents of CA$18.9 million, against CA$171,271 a year earlier (+10,906.7%). Source: the 20-F filed with the SEC on May 3, 2022. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:XRTX&period_type=annual&limit=5"Information only, not investment advice.